• Continuing medical education significantly influences prescribing behaviors, but commercial bias can undermine evidence-based practice.
• Digital education platforms offer scalable solutions for improving drug knowledge and access, yet require robust oversight.
• Regulatory frameworks must adapt to address conflicts of interest in pharmaceutical-sponsored education.
• Integrating real-world evidence into CME can enhance clinical decision-making and patient outcomes.